BioCryst Q1 ORLADEYO revenue rises 11%, net loss widens

BioCryst Pharmaceuticals

06/05/2026 12:20

Overview

US rare disease drugmaker's Q1 ORLADEYO revenue rose 11% yr/yr, driven by new prescriptions

GAAP net loss widened on special, non-cash charge from Astria Therapeutics acquisition

Company announced $70 mln upfront licensing deal for European navenibart rights, plus potential milestones

Outlook

BioCryst expects 2026 global net ORLADEYO revenue of $625 mln to $645 mln

Company maintains 2026 total revenue guidance at $635 mln to $660 mln

BioCryst expects 2026 non-GAAP operating expenses of $450 mln to $470 mln

Result Drivers

ORLADEYO PRESCRIPTION GROWTH - Co said Q1 revenue growth was driven by strong new patient prescriptions for ORLADEYO

LICENSING AGREEMENT - Co received $70 mln upfront from licensing European rights to navenibart, with potential for additional milestone payments

Company press release: ID:nGNX11XrgW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Total Revenue
$156.4 mln
Q1 EPS
-$2.98
Q1 Net Income
-$721.81 mln
Q1 Operating Expenses
$858.01 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $20.00, about 121.5% above its May 5 closing price of $9.03

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)